Postibrutinib outcomes in patients with mantle cell lymphoma
Peter Martin(Northwestern University), Kristie A. Blum(Emory University), Stephen E. Spurgeon(Oregon Health & Science University), Richard R. Furman(Cornell University), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Stephan Stilgenbauer(Universität Ulm), Craig A. Portell(University of Virginia), Kami J. Maddocks(The Ohio State University), Eliana Kozin(Oregon Health & Science University), David Iberri(Stanford University), John P. Leonard(New York University), Martin Dreyling(LMU Klinikum), Johannes Bloehdorn(Universitätsklinikum des Saarlandes), Jia Ruan(Cornell University), Paul M. Barr(University of Rochester Medical Center), Simon Rule(AstraZeneca (United Kingdom)), Ranjana H. Advani(Stanford Medicine), Tycel Phillips(Michigan Medicine), Ewa Chmielowska(Centrum Onkologii), Katherine Noto(Cornell University), André Goy(Hackensack University Medical Center), Zhengming Chen(Cornell University), Michael E. Williams(University of Virginia), Wojciech Jurczak(Jagiellonian University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Maurizio DiLiberto(NewYork–Presbyterian Hospital), Rebecca Auer(St Bartholomew's Hospital)
Cited by 289
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k